文献速递基础与转化研究临床试验与 GCP组学、生物样本库与精准医学

CDK4/6抑制剂早期与延迟使用在晚期乳腺癌中的对比:一项随机3期试验的循环肿瘤DNA分析

Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer: circulating tumor DNA analysis of a randomized phase 3 trial.
PubMed 文献 · Nat Med · 2025-09-04

本研究基于SONIA 3期试验,对409例晚期雌激素受体阳性、HER2阴性乳腺癌患者一线治疗前血浆游离DNA进行全基因组非整倍体评分,以评估ctDNA水平能否识别从一线CDK4/6抑制剂治疗中获益的患者。高非整倍体组(评分≥5)一线与二线CDK4/6抑制剂策略的PFS2风险比为0.58(95%CI 0.38-0.88),低非整倍体组为1.36(95%CI 0.95-1.96),治疗策略与非整倍体评分对PFS2存在显著交互作用(P=0.004)。

要点

  • 治疗前ctDNA水平可用于识别从一线CDK4/6抑制剂治疗中获益的患者。
  • 高非整倍体组一线CDK4/6抑制剂策略PFS2风险比为0.58(95%CI 0.38-0.88)。
  • 治疗策略与非整倍体评分对PFS2存在显著交互作用(P=0.004)。

核心结论

  • 治疗前ctDNA水平可用于识别从一线CDK4/6抑制剂治疗中获益的患者。

研究设计与样本

  • 基于SONIA 3期随机试验的探索性研究,纳入409例参与SONIA的女性患者,分析一线治疗前血浆游离DNA。
  • 采用改良快速非整倍体筛查测序系统检测,获得指示ctDNA水平的全基因组非整倍体评分。

主要发现

  • 409例患者中141例基线全基因组非整倍体评分高。
  • 高非整倍体组一线与二线CDK4/6抑制剂策略的PFS2风险比为0.58(95%CI 0.38-0.88)。
  • 低非整倍体组一线与二线CDK4/6抑制剂策略的PFS2风险比为1.36(95%CI 0.95-1.96)。
  • 治疗策略与非整倍体评分对PFS2存在显著交互作用(P=0.004)。

关键数值与推荐

  • 高非整倍体组定义为全基因组非整倍体评分≥5。
  • 低非整倍体组定义为全基因组非整倍体评分<5。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CDK4/6 inhibitors (CDK4/6i) improve outcome in patients with advanced estrogen receptor-positive, HER2- breast cancer. The phase 3 SONIA trial compared the addition of CDK4/6i to first- versus second-line endocrine therapy for time to disease progression after second-line treatment (progression-free survival after two lines of treatment (PFS2)), as well as for secondary outcomes overall survival, PFS after one line of treatment (PFS1), health-related quality of life (HRQOL), toxicity and cost-effectiveness. No significant difference in PFS2 was observed; however, on an individual patient level this may be different. Using prespecified circulating tumor DNA analyses, we performed an exploratory study to evaluate whether pretreatment circulating tumor DNA (ctDNA) levels in plasma can identify patients that benefit from CDK4/6i during their first-line treatment. Cell free DNA before start of first-line treatment from 409 female patients participating in SONIA was analyzed with the modified fast aneuploidy screening test-sequencing system. This assay yields a genome-wide aneuploidy score, indicative of ctDNA levels. Cox proportional hazard analyses for PFS1 and PFS2 were performed separately for the ctDNA high group (aneuploidy score ≥ 5) and the ctDNA low group (aneuploidy score < 5). In total, 141 of the 409 included patients had a high genome-wide aneuploidy score at baseline. PFS2 in the first- compared to the second-line CDK4/6i strategy showed hazard ratios of 0.58 (95% confidence interval 0.38-0.88) and 1.36 (95% confidence interval 0.95-1.96) in the high and low aneuploidy group, respectively. A significant interaction was demonstrated between treatment strategy and aneuploidy score for PFS2 (P = 0.004). In conclusion, this study demonstrated that pretreatment ctDNA levels can be used to identify patients that benefit from first-line CDK4/6i treatment. ClinicalTrials.gov registration: NCT03425838 .

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Jongbloed EM, Wortelboer N, de Weerd V, et al. Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer: circulating tumor DNA analysis of a randomized phase 3 trial. Nat Med. 2025. PMID: 40908356. doi:10.1038/s41591-025-03935-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。